Covishield And Covaxin

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

In his letter to the prime minister, Congress leader Adhir Ranjan Chowdhury claimed that there is a lack of availability of Covaxin and Covishield, and most children below 18 years remain unprotected

Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.

The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.

Neutralising antibody levels waned after six months in those who were fully vaccinated against the coronavirus with Covishield, Covaxin and a mix of both with regard to Omicron variant, a study done by the National Institute of Virology indicated.

Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.

India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.

Covaxin and Covishield could be more widely available with a new government approval that also suggests changes in rules for booster doses. Both vaccines have been cleared for "full use" by an expert panel of the central drug authority, a year after

An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said

Maharashtra is facing a shortage of Covaxin and Covishield, said state health minister Rajesh Tope on Thursday.

The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.

New Zealand has included Covaxin and Covishield to its list of eight approved vaccines, Indian High Commissioner to the country, Mukhtesh Pardeshi, said today.

Union Health Minister Mansukh Mandaviya said on Tuesday that 96 countries have recognised Covaxin and Covishield and both these COVID-19 vaccines have received emergency use listing (EUL) from the World Health Organisation (WHO).

Earlier, the Therapeutic Goods Administration (TGA) had recommended that only the vaccines approved for use in Australia, and Covishield from India and Sinovac from China be recognised for the purposes of travel and other restrictions.

Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

In his letter to the prime minister, Congress leader Adhir Ranjan Chowdhury claimed that there is a lack of availability of Covaxin and Covishield, and most children below 18 years remain unprotected

Serum Institute of India CEO Adar Poonawalla and Bharat Biotech cofounder Suchitra Ella today said that the decision was taken after discussions with the Centre.

The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.

Neutralising antibody levels waned after six months in those who were fully vaccinated against the coronavirus with Covishield, Covaxin and a mix of both with regard to Omicron variant, a study done by the National Institute of Virology indicated.

Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.

India's drug regulator has granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said today.

Covaxin and Covishield could be more widely available with a new government approval that also suggests changes in rules for booster doses. Both vaccines have been cleared for "full use" by an expert panel of the central drug authority, a year after

An expert panel of India's central drug authority today recommended granting regular market approval to Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said

Maharashtra is facing a shortage of Covaxin and Covishield, said state health minister Rajesh Tope on Thursday.

The Central Drugs Standard Organisation (CDSO) has approved the shelf life of COVID-19 vaccines Covaxin to 12 months, Covishield to nine months, and ZyCoV-D to six months from the date of manufacture, the Lok Sabha was informed on Friday.

New Zealand has included Covaxin and Covishield to its list of eight approved vaccines, Indian High Commissioner to the country, Mukhtesh Pardeshi, said today.

Union Health Minister Mansukh Mandaviya said on Tuesday that 96 countries have recognised Covaxin and Covishield and both these COVID-19 vaccines have received emergency use listing (EUL) from the World Health Organisation (WHO).

Earlier, the Therapeutic Goods Administration (TGA) had recommended that only the vaccines approved for use in Australia, and Covishield from India and Sinovac from China be recognised for the purposes of travel and other restrictions.

Zydus Cadila's ZyCov-D is the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above